ASRT Assertio
- 1.070
- +0.050+4.90%
- 1.061
- -0.009-0.85%
Assertio News
Assertio to Participate in Benchmark Healthcare Conference on May 21-22
LAKE FOREST, Ill., May 17, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated
Assertio to Participate in AGP Healthcare Conference on May 21
LAKE FOREST, Ill., May 16, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated
Assertio to Present at the Citizens JMP Life Sciences Conference in New York City
LAKE FOREST, Ill., May 10, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated
Assertio Holdings First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Assertio Holdings Shares Are Trading Lower. The Company Reported Q1 Financial Results.
Assertio Holdings Shares Are Trading Lower. The Company Reported Q1 Financial Results.
Assertio Holdings, Inc. (NASDAQ:ASRT) Q1 2024 Earnings Call Transcript
Analysts Offer Insights on Healthcare Companies: Assertio Therapeutics (ASRT), Longboard Pharmaceuticals (LBPH) and Travere Therapeutics (TVTX)
Assertio Holdings, Inc.'s (NASDAQ:ASRT) Share Price Boosted 29% But Its Business Prospects Need A Lift Too
Assertio Holdings, Inc. (NASDAQ:ASRT) shares have continued their recent momentum with a 29% gain in the last month alone. Still, the 30-day jump doesn't change the fact that longer term shareholde
Q1 2024 Assertio Holdings Inc Earnings Call
Assertio Holdings Inc (ASRT) Q1 2024 Earnings Call Transcript Highlights: A Detailed Review of ...
Assertio Holdings, Inc. (ASRT) Q1 2024 Earnings Call Transcript
Assertio Holdings, Inc. (ASRT) Q1 2024 Earnings Call Transcript
Assertio | 10-Q: Quarterly report
Earnings Flash (ASRT) ASSERTIO HOLDINGS Posts Q1 Revenue $32.4M, Vs. Street Est of $29.5M
04:09 PM EDT, 05/06/2024 (MT Newswires) -- Earnings Flash (ASRT) ASSERTIO HOLDINGS Posts Q1 Revenue $32.4M, vs. Street Est of $29.5M
Assertio Holdings Q1 2024 Adj EPS $0.04 Beats $(0.03) Estimate, Sales $32.448M Beat $29.512M Estimate
Assertio Holdings (NASDAQ:ASRT) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $(0.03) by 233.33 percent. This is a 86.21 percent decrease over earnings of
Assertio Holdings: Reiterating Guidance for 2024, Calling for Net Pdt Sales of $110M to $125M and Adjusted EBITDA of $20M to $30M >ASRT
Assertio Holdings: Reiterating Guidance for 2024, Calling for Net Pdt Sales of $110M to $125M and Adjusted EBITDA of $20M to $30M >ASRT
Assertio Holdings 1Q Loss/Shr 5c >ASRT
Assertio Holdings 1Q Loss/Shr 5c >ASRT
Press Release: Assertio Reports First Quarter 2024 Financial Results
Assertio Reports First Quarter 2024 Financial Results First Quarter Net Product Sales of $31.9 Million Rolvedon Growth Continues, with $14.5 million in Net Product Sales $7.5 Million in Cash Flow f
Assertio Reports First Quarter 2024 Financial Results
Assertio Holdings, Inc. to Report First Quarter 2024 Financial Results on May 6, 2024
LAKE FOREST, Ill., April 25, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated
323 drugs, hurry up! America is facing the biggest “drug shortage” in history...
The US now seems to be facing an unprecedented “drug shortage”...
Analysis
Price Target
No Data
